$13.00
0.645.18%
Últ. Act.: Oct 21, 10:39 AM
$12.30
-0.06-0.49%
Avalo Therapeutics (AVTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.63 | $-1.01 | $-1.51 | $-1.65 |
| Actual | $-0.83 | $-0.98 | $-0.48 | $-2.19 |
| Surprise | -31.8% | +2.97% | +68.2% | -32.7% |
| Revenue | ||||
| Estimate | — | — | — | — |
| Actual | $0 | $0 | $59000 | $0 |
| Surprise | — | — | — | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.58 | $-0.55 | $-0.68 | $-0.74 |
| Revenue | ||||
| Consensus | — | — | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.83 | $-0.63 | -31.8 % |
| Q1 | May 13, 2026 | $-0.98 | $-1.01 | 2.97 % |
| Q4 | Mar 23, 2026 | $-0.48 | $-1.51 | 68.2 % |
| Q3 | Nov 6, 2025 | $-2.19 | $-1.65 | -32.7 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q4 | Mar 29, 2024 | $571.00K | $300.00K | 90.3 % |
| Q3 | Nov 9, 2023 | $236.00K | $1.00M | -76.4 % |
| Q2 | Aug 3, 2023 | $643.00K | $500.00K | 28.6 % |
| Q1 | May 4, 2023 | $475.00K | $1.00M | -52.5 % |